For example, BI-RADS 3 lesions in high-risk patients, patients awaiting organ transplant, patients with known synchronous cancers, or patients trying to get pregnant may be appropriate for tissue sampling. In addition, situations in which biopsy may alleviate extreme patient anxiety may prompt tissue sampling, and a biopsy marker clip should be placed [30]. However, large series demonstrate that core biopsy is superior to FNAB in terms of sensitivity, specificity, and correct histological grading of palpable masses [27]. In addition, core biopsy allows for ready evaluation of tumor receptor status. US-guided FNAB may be preferred in rare situations (lesion abuts an implant). Mammography Diagnostic If a correlate for a palpable mass has been identified on US and is probably benign, there is no indication for diagnostic mammography to further evaluate the palpable mass in women <30 years of age. Palpable Breast Masses Mammography Screening In women presenting with signs or symptoms, including a palpable breast mass, screening mammography is unnecessary for imaging surveillance. Screening mammography is provided to women without signs or symptoms of breast disease. MRI Breast There is no relevant literature to support the use of the use of MRI of the breast with or without IV contrast in women <30 years of age with probably benign sonographic findings in the setting of a palpable mass [2,23-25]. Sestamibi MBI There is no relevant literature to support the use of the use of Tc-99m sestamibi MBI in women <30 years of age with probably benign sonographic findings in the setting of a palpable mass. Variant 9: Adult female, younger than 30 years of age. Palpable breast mass. US findings benign (BI-RADS 2). Next imaging study. Digital Breast Tomosynthesis Diagnostic If a benign entity has been found on US and is the definitive correlate for a palpable mass, there is no role for further evaluation with diagnostic DBT in women <30 years of age.
Palpable Breast Masses. For example, BI-RADS 3 lesions in high-risk patients, patients awaiting organ transplant, patients with known synchronous cancers, or patients trying to get pregnant may be appropriate for tissue sampling. In addition, situations in which biopsy may alleviate extreme patient anxiety may prompt tissue sampling, and a biopsy marker clip should be placed [30]. However, large series demonstrate that core biopsy is superior to FNAB in terms of sensitivity, specificity, and correct histological grading of palpable masses [27]. In addition, core biopsy allows for ready evaluation of tumor receptor status. US-guided FNAB may be preferred in rare situations (lesion abuts an implant). Mammography Diagnostic If a correlate for a palpable mass has been identified on US and is probably benign, there is no indication for diagnostic mammography to further evaluate the palpable mass in women <30 years of age. Palpable Breast Masses Mammography Screening In women presenting with signs or symptoms, including a palpable breast mass, screening mammography is unnecessary for imaging surveillance. Screening mammography is provided to women without signs or symptoms of breast disease. MRI Breast There is no relevant literature to support the use of the use of MRI of the breast with or without IV contrast in women <30 years of age with probably benign sonographic findings in the setting of a palpable mass [2,23-25]. Sestamibi MBI There is no relevant literature to support the use of the use of Tc-99m sestamibi MBI in women <30 years of age with probably benign sonographic findings in the setting of a palpable mass. Variant 9: Adult female, younger than 30 years of age. Palpable breast mass. US findings benign (BI-RADS 2). Next imaging study. Digital Breast Tomosynthesis Diagnostic If a benign entity has been found on US and is the definitive correlate for a palpable mass, there is no role for further evaluation with diagnostic DBT in women <30 years of age.